From the President's Desk:

Yuji Matsuzawa

As the incoming President of the IAS beginning January 1, 2016, I am very happy to introduce our new team of Officers, the Executive Committee, and Executive Board. Please visit our website at www.athero.org for complete information and brief biographies on each member of our valuable team.

President
Yuji Matsuzawa, MD, PhD
Director, Sumitomo Hospital, Osaka, Japan

President-Elect
Raul Santos, MD, MSc, PhD
Director of Lipid Clinic, Heart Institute, University of São Paulo Medical, School Hospital, Sao Paulo, Brazil
>Complete Article<

Also included in this newsletter:

• FEATURED COMMENTARIES
   
• JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
   
• ATHEROSCLEROSIS JOURNAL NEWSLETTER
  Volume 245 Issue February 2016
   
• ​UPCOMING MEETINGS​
   
• RECOMMENDATIONS FROM THE READERS

This new brochure includes
the list of the incoming IAS Board and Officers (2016-2018)
and the new member societies.
Click to View

IAS WEBSITE FEATURED CONNECTIONS

• Recent Clinical Trials
   
• Cardiovascular Guidelines
   
• Commentaries
   
• ​Slide Library
   
• Website Links

• 3 - Month Visiting Fellowship Award $5,000
• 6 - Month Visiting Fellowship Award $8,000
For more information Click Here

St. Petersburg, Russia
June 2 - 4, 2016
 

In the News:

• Special issue highlights new heart disease research on women, call for more
 
• Smoking and inactivity lead to alarming rise in heart attacks among young Indians
 
• Dietary Guidelines Statement from American College of Cardiology
 
• Rapid symptom improvement may not indicate better stroke recovery
 
• First European advice launched for deadly acute heart failure

LITERATURE UPDATES

SEARCH BY TOPIC:
 
Aging
 
Apo/Lipoproteins
 
Biomarkers
 
Clinical Trails
 
Diabetes
 
Diet and Nutrition
 
Drug Therapy
 
Epidemiology
 
Gender
 
Genetics of Cardiovascular Disease
 
Hypertension
 
Imaging
 
Immunology
 
Inflammation
 
Life Style
 
Menopause
 
Metabolic Syndrome
 
Miscellaneous
 
Oxidative Stress/Antioxidants
 
Plaque Biology
 
Renal Disease
 
Risk Assessment
 
Risk Factor
 
Stroke
 
Vascular Biology
 
Vascular Calcification

Toronto, Canada
June 9 - 15, 2018
 

FEATURED COMMENTARIES:

Anti-inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis

In the early 1990s, Dr. Ross proposed the chronic inflammation hypothesis of atherosclerosis (AS). He further clearly regarded AS as an inflammatory disease in 1999. With more and more inflammatory cells and mediators constantly being detected, AS is no longer considered a simple disease of lipid deposition onto the arterial wall, but instead a progressive inflammatory response within the vessel wall.
 

A Monocyte/Macrophage-Based Model for Studying Immunopathology Relevant For Diagnostics and Drug Development for Atherosclerosis

Beyond Curcumin: Anti-atherosclerotic Effect of Turmeric

Atherosclerosis is a chronic disease of the arterial wall which is polygenic in nature. It involves several interconnected perturbations including dyslipidemia, inflammation, oxidative stress, endothelial dysfunction, and platelet activation. Since atherosclerosis is considered a lifestyle disorder and develops over many years, its long-term management can hold the key for successful prevention and therapy. Therefore, incorporation of functional foods in the daily diet may help manage the disease better.
 

Atherosclerosis, Chronic Kidney Disease, and Cathepsin S

Atherosclerosis is a leading cause of mortality in patients with chronic kidney disease (CKD), which characterizes by extensive remodeling of the extracellular matrix in the arterial wall. Arterial inflammation is the key aspect of the formation and progression of atherosclerotic lesions. However, other molecular mechanisms are involved in the response to the injury of the vascular wall and development of atherosclerosis.
 

UPCOMING MEETINGS:

Acknowledgements
The IAS wishes to thank all the supporters which have generously offered grants to the IAS
for the development of its many activities and in support of its mission during 2015:
Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini,
OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd., Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College.

IAS Newsletter Editors
&
Website Editorial Board

Editor-in-Chief
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Associate Editors
Stefano Bellosta, PhD
Milan, Italy
Emanuela Folco, PhD
Milan, Italy
Ann Jackson, MBA
Houston, TX, USA
Website & Newsletter Editors
Elena Colombo
Milan, Italy
Yelonda Williams, BA
Dallas, TX, USA